Discovery of Small Molecule COX-1 and Akt Inhibitors as Anti-NSCLC Agents Endowed with Anti-Inflammatory Action
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms24032648 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Mehlika Dilek Altıntop und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Anadolu University, 26470 Eskişehir, Turkey. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 89 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Anadolu University, Anadolu University Scientific Research Projects Commission.
Abstract (Originalsprache)
Targeted therapies have come into prominence in the ongoing battle against non-small cell lung cancer (NSCLC) because of the shortcomings of traditional chemotherapy. In this context, indole-based small molecules, which were synthesized efficiently, were subjected to an in vitro colorimetric assay to evaluate their cyclooxygenase (COX) inhibitory profiles. Compounds 3b and 4a were found to be the most selective COX-1 inhibitors in this series with IC50 values of 8.90 µM and 10.00 µM, respectively. In vitro and in vivo assays were performed to evaluate their anti-NSCLC and anti-inflammatory action, respectively. 2-(1H-Indol-3-yl)-N′-(4-morpholinobenzylidene)acetohydrazide (3b) showed selective cytotoxic activity against A549 human lung adenocarcinoma cells through apoptosis induction and Akt inhibition. The in vivo experimental data revealed that compound 3b decreased the serum myeloperoxidase and nitric oxide levels, pointing out its anti-inflammatory action. Moreover, compound 3b diminished the serum aminotransferase (particularly aspartate aminotransferase) levels. Based on the in vitro and in vivo experimental data, compound 3b stands out as a lead anti-NSCLC agent endowed with in vivo anti-inflammatory action, acting as a dual COX-1 and Akt inhibitor.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Anadolu University, 26470 Eskişehir, Turkey.
- Department of Biochemistry, Faculty of Pharmacy, Anadolu University, 26470 Eskişehir, Turkey.
- Graduate School of Health Sciences, Anadolu University, 26470 Eskişehir, Turkey.
- Department of Medical Biochemistry, Faculty of Medicine, Eskisehir Osmangazi University, 26480 Eskişehir, Turkey.
ORCID-Profile: Mehlika Dilek Altıntop, Betül Can, Belgin Sever, Ahmet Özdemir
Förderung
- Anadolu University
- Anadolu University Scientific Research Projects Commission
Zitieren
APA
Altıntop, M. D., Akalın Çiftçi, G., Yılmaz Savaş, N., Ertorun, İ., Can, B., Sever, B., Temel, H. E., Alataş, Ö., & Özdemir, A. (2023). Discovery of Small Molecule COX-1 and Akt Inhibitors as Anti-NSCLC Agents Endowed with Anti-Inflammatory Action. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24032648
Vancouver
Altıntop MD, Akalın Çiftçi G, Yılmaz Savaş N, Ertorun İ, Can B, Sever B, et al. Discovery of Small Molecule COX-1 and Akt Inhibitors as Anti-NSCLC Agents Endowed with Anti-Inflammatory Action. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24032648
BibTeX
@article{Altntop2023,
author = {Altıntop, Mehlika Dilek and Akalın Çiftçi, Gülşen and Yılmaz Savaş, Nalan and Ertorun, İpek and Can, Betül and Sever, Belgin and Temel, Halide Edip and Alataş, Özkan and Özdemir, Ahmet},
title = {Discovery of Small Molecule COX-1 and Akt Inhibitors as Anti-NSCLC Agents Endowed with Anti-Inflammatory Action},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms24032648}
}
EUVIMED